{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:24:03Z","timestamp":1761578643124},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n            <jats:title>Aim:<\/jats:title>\n            <jats:p>The objective of this article is to review the contemporary literature on the use of antithrombotic therapy in patients with atrial fibrillation (AF) and coronary artery disease after undergoing percutaneous coronary intervention (PCI). Special consideration was given to the type and duration of therapy, treatment strategies for the elderly (\u226565 years of age), and strategies to reduce bleeding.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Relevant studies were searched through MEDLINE\/PubMed, Web of Science, Cochrane Library, ClinicalTrials.gov, and Google Scholar. Of the 236 publications retrieved, 76 were considered relevant including 35 randomized controlled trials, 17 meta-analyses, 16 observational studies, and 8 published major guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Most trials, meta-analyses, and guidelines support 1 month of triple therapy (TT) with an oral anticoagulant (OAC), dual antiplatelet agents (DAPT) with aspirin (ASA)\/clopidogrel, and, afterward, dual therapy (DT) with OAC and single antiplatelet agent for an additional 11 months, or alternatively DT alone for 12 months after PCI. Individual consideration is given to the risk and impact of stent thrombosis (ST), thromboembolism, and bleeding. Several trials and meta-analyses have also suggested that shorter DAPT duration (\u22646 months) may be safer than longer therapy (\u22656 months) when weighing the risk of bleeding with ischemic outcomes, especially with newer generation drug-eluting stents. The selective use of proton-pump inhibitors in patients prone to gastrointestinal bleeding who are subjected to prolonged exposure with TT or DT may be beneficial. In the elderly, the risk of bleeding from TT, compared with DT, outweighs the benefit of reducing ischemic events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In conclusion, tailoring therapy to the individual patient is recommended considering the ischemic and bleeding risk as well as the risk of thromboembolism. For most patients with AF, 1 month of TT and subsequently DT for additional 11 months are recommended.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/fjc.0000000000000697","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T12:21:17Z","timestamp":1563193277000},"page":"82-90","source":"Crossref","is-referenced-by-count":5,"title":["Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention"],"prefix":"10.1097","volume":"74","author":[{"given":"Abhishek","family":"Mishra","sequence":"first","affiliation":[{"name":"Heart and Vascular Center, Guthrie\/Robert Packer Hospital, Sayre, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maninder","family":"Singh","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Guthrie\/Robert Packer Hospital, Sayre, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warren W.","family":"Acker","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Guthrie\/Robert Packer Hospital, Sayre, PA;"},{"name":"Geisinger Commonwealth School of Medicine, Scranton, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukriti","family":"Kamboj","sequence":"additional","affiliation":[{"name":"East Carolina University, Greenville NC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Sporn","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Guthrie\/Robert Packer Hospital, Sayre, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwight","family":"Stapleton","sequence":"additional","affiliation":[{"name":"OSF Healthcare System, University of Illinois College of Medicine, Peoria, IL; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edo","family":"Kaluski","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Guthrie\/Robert Packer Hospital, Sayre, PA;"},{"name":"Geisinger Commonwealth School of Medicine, Scranton, PA;"},{"name":"Rutgers University, New Brunswick, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230911","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a Cohort Study","volume":"386","author":"Schnabel","year":"20152015","journal-title":"Lancet."},{"key":"R2-20230911","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J."},{"key":"R3-20230911","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"R4-20230911","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","article-title":"Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation."},{"key":"R5-20230911","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med."},{"key":"R6-20230911","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jacc.2010.10.029","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial","volume":"57","author":"Held","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"R7-20230911","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET Study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation."},{"key":"R8-20230911","first-page":"e362","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation."},{"key":"R9-20230911","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"Sorensen","year":"2009","journal-title":"Lancet."},{"key":"R10-20230911","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","article-title":"2018 joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)","volume":"21","author":"Lip","year":"2019","journal-title":"Europace."},{"key":"R11-20230911","doi-asserted-by":"crossref","first-page":"e24964","DOI":"10.1371\/journal.pone.0024964","article-title":"Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography","volume":"6","author":"Kralev","year":"2011","journal-title":"PLoS One."},{"key":"R12-20230911","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.cjca.2018.08.026","article-title":"2018 focused update of the Canadian cardiovascular society guidelines for the management of atrial fibrillation","volume":"34","author":"Andrade","year":"2018","journal-title":"Can J Cardiol."},{"key":"R13-20230911","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest."},{"key":"R14-20230911","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective\u20132018 update","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation."},{"key":"R15-20230911","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J."},{"key":"R16-20230911","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet."},{"key":"R17-20230911","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med."},{"key":"R18-20230911","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med."},{"key":"R19-20230911","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation."},{"key":"R20-20230911","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med."},{"key":"R21-20230911","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jcin.2015.08.018","article-title":"Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study","volume":"8","author":"Jackson","year":"2015","journal-title":"JACC Cardiovasc Interv."},{"key":"R22-20230911","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.amjcard.2017.12.014","article-title":"Meta-analysis comparing the safety and efficacy of dual versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"121","author":"Cavallari","year":"2018","journal-title":"Am J Cardiol."},{"key":"R23-20230911","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/eurheartj\/ehy162","article-title":"Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials","volume":"39","author":"Golwala","year":"2018","journal-title":"Eur Heart J."},{"key":"R24-20230911","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet."},{"key":"R25-20230911","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1001\/jama.2013.278787","article-title":"Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents","volume":"310","author":"Hawn","year":"2013","journal-title":"JAMA."},{"key":"R26-20230911","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurheartj\/ehs460","article-title":"Should duration of dual antiplatelet therapy depend on the type and\/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)","volume":"34","author":"Valgimigli","year":"2013","journal-title":"Eur Heart J."},{"key":"R27-20230911","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa067193","article-title":"Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents","volume":"356","author":"Stone","year":"2007","journal-title":"N Engl J Med."},{"key":"R28-20230911","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1056\/NEJMoa067484","article-title":"Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents","volume":"356","author":"Kastrati","year":"2007","journal-title":"N Engl J Med."},{"key":"R29-20230911","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(07)61444-5","article-title":"Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis","volume":"370","author":"Stettler","year":"2007","journal-title":"Lancet."},{"key":"R30-20230911","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med."},{"key":"R31-20230911","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1161\/CIRCULATIONAHA.112.097014","article-title":"Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials","volume":"125","author":"Bangalore","year":"2012","journal-title":"Circulation."},{"key":"R32-20230911","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(13)61782-1","article-title":"Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials","volume":"382","author":"Stefanini","year":"2013","journal-title":"Lancet."},{"key":"R33-20230911","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(11)61672-3","article-title":"Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial","volume":"378","author":"Stefanini","year":"2011","journal-title":"Lancet."},{"key":"R34-20230911","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(12)60324-9","article-title":"Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis","volume":"379","author":"Palmerini","year":"2012","journal-title":"Lancet."},{"key":"R35-20230911","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med."},{"key":"R36-20230911","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med."},{"key":"R37-20230911","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.jcin.2016.05.039","article-title":"Use of dual antiplatelet therapy and patient outcomes in those undergoing percutaneous coronary intervention: the ROCKET AF trial","volume":"9","author":"Sherwood","year":"2016","journal-title":"JACC Cardiovasc Interv."},{"key":"R38-20230911","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jacc.2018.04.036","article-title":"Risk of myocardial infarction in anticoagulated patients with atrial fibrillation","volume":"72","author":"Lee","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"R39-20230911","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.jacc.2018.07.054","article-title":"Combining oral anticoagulants with platelet inhibitors in patients with atrial fibrillation and coronary disease","volume":"72","author":"Sindet-Pedersen","year":"2018","journal-title":"J Am Coll Cardiol."},{"issue":"suppl 6","key":"R40-20230911","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1136\/heartjnl-2016-309890.36","article-title":"36 Triple therapy anticoagulation following percutaneous coronary intervention (PCI) with novel oral anticoagulants (NOAC) is safe and has no adverse effects on bleeding post procedure when compared to triple therapy with vitamin k antagonist (VKA)","volume":"102","author":"Amin","year":"2016","journal-title":"Heart."},{"key":"R41-20230911","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","article-title":"Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation","volume":"61","author":"Sarafoff","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"R42-20230911","doi-asserted-by":"crossref","first-page":"e003946","DOI":"10.1161\/JAHA.116.003946","article-title":"Factors associated with initial prasugrel versus clopidogrel selection for patients with acute myocardial infarction undergoing percutaneous coronary intervention: insights from the treatment with adp receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study","volume":"5","author":"Vora","year":"2016","journal-title":"J Am Heart Assoc."},{"key":"R43-20230911","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet."},{"key":"R44-20230911","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.cjca.2014.07.102","article-title":"Ticagrelor versus clopidogrel among patients using triple therapy after percutaneous coronary internvetion: the capital ATACC study","volume":"30","author":"Fu","year":"2014","journal-title":"Can J Cardio."},{"key":"R45-20230911","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/clc.22486","article-title":"Ticagrelor in triple antithrombotic therapy: predictors of ischemic and bleeding complications","volume":"39","author":"Fu","year":"2016","journal-title":"Clin Cardiol."},{"key":"R46-20230911","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of xience\/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation."},{"key":"R47-20230911","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA."},{"key":"R48-20230911","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"R49-20230911","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"R50-20230911","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Schupke","year":"2015","journal-title":"Eur Heart J."},{"key":"R51-20230911","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet."},{"key":"R52-20230911","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/eurheartj\/ehv038","article-title":"Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment after Grading Stent-Induced Intimal Hyperplasia) trial","volume":"36","author":"Costa","year":"2015","journal-title":"Eur Heart J."},{"key":"R53-20230911","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation."},{"key":"R54-20230911","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","article-title":"Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials","volume":"385","author":"Palmerini","year":"2015","journal-title":"Lancet."},{"key":"R55-20230911","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1093\/eurheartj\/ehs318","article-title":"Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials","volume":"33","author":"Cassese","year":"2012","journal-title":"Eur Heart J."},{"key":"R56-20230911","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"R57-20230911","doi-asserted-by":"crossref","first-page":"h1618","DOI":"10.1136\/bmj.h1618","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials","volume":"350","author":"Navarese","year":"2015","journal-title":"BMJ."},{"key":"R58-20230911","doi-asserted-by":"crossref","first-page":"i5483","DOI":"10.1136\/bmj.i5483","article-title":"Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials","volume":"355","author":"Gargiulo","year":"2016","journal-title":"BMJ."},{"key":"R59-20230911","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med."},{"key":"R60-20230911","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet."},{"key":"R61-20230911","first-page":"1034","article-title":"Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients","volume":"38","author":"Palmerini","year":"2017","journal-title":"Eur Heart J."},{"key":"R62-20230911","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"R63-20230911","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jcin.2015.10.001","article-title":"Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents","volume":"9","author":"Hermiller","year":"2016","journal-title":"JACC Cardiovasc Interv."},{"key":"R64-20230911","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2016.04.118","article-title":"Duration of dual antiplatelet therapy after various drug-eluting stent implantation","volume":"215","author":"Sharma","year":"2016","journal-title":"Int J Cardiol."},{"key":"R65-20230911","doi-asserted-by":"crossref","first-page":"k3793","DOI":"10.1136\/bmj.k3793","article-title":"Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial","volume":"363","author":"Kedhi","year":"2018","journal-title":"BMJ."},{"key":"R66-20230911","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jamacardio.2018.3551","article-title":"Efficacy and safety of drug-eluting stents optimized for biocompatibility vs bare-metal stents with a single month of dual antiplatelet therapy: a meta-analysis","volume":"3","author":"Shah","year":"2018","journal-title":"JAMA Cardiol."},{"key":"R67-20230911","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Schomig","year":"1996","journal-title":"N Engl J Med."},{"key":"R68-20230911","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and risks of extended duration dual antiplatelet therapy after pci in patients with and without acute myocardial infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"R69-20230911","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jacc.2015.05.062","article-title":"Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation","volume":"66","author":"Hess","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"R70-20230911","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ahj.2012.01.017","article-title":"Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction","volume":"163","author":"Fosbol","year":"2012","journal-title":"Am Heart J."},{"key":"R71-20230911","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J."},{"key":"R72-20230911","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jcin.2017.10.015","article-title":"Short-term versus long-term dual antiplatelet therapy after drug-eluting stent implantation in elderly patients: a meta-analysis of individual participant data from 6 randomized trials","volume":"11","author":"Lee","year":"2018","journal-title":"JACC Cardiovasc Interv."},{"key":"R73-20230911","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med."},{"key":"R74-20230911","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ahj.2015.07.030","article-title":"Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: optimization of antiplatelet treatment in patients 70 years and older\u2014rationale and design of the POPular AGE study","volume":"170","author":"Qaderdan","year":"2015","journal-title":"Am Heart J."},{"key":"R75-20230911","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa012877","article-title":"Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use","volume":"346","author":"Lai","year":"2002","journal-title":"N Engl J Med."},{"key":"R76-20230911","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med."},{"key":"R77-20230911","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2018.17242","article-title":"Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding","volume":"320","author":"Ray","year":"2018","journal-title":"JAMA."},{"key":"R78-20230911","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1053\/j.gastro.2018.06.063","article-title":"Proton pump inhibitors are underprescribed in patients discharged on dual antiplatelet therapy after acute coronary syndrome","volume":"155","author":"Hartman","year":"2018","journal-title":"Gastroenterology."},{"key":"R79-20230911","doi-asserted-by":"crossref","first-page":"e0124653","DOI":"10.1371\/journal.pone.0124653","article-title":"Proton pump inhibitor usage and the risk of myocardial infarction in the general population","volume":"10","author":"Shah","year":"2015","journal-title":"PLoS One."},{"key":"R81-20230911","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O'Donoghue","year":"2009","journal-title":"Lancet."},{"key":"R82-20230911","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ahj.2016.01.015","article-title":"Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial","volume":"174","author":"Gargiulo","year":"2016","journal-title":"Am Heart J."},{"key":"R83-20230911","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.111.032912","article-title":"Patient Outcomes Trial I. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial","volume":"125","author":"Goodman","year":"2012","journal-title":"Circulation."},{"key":"R84-20230911","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"N Engl J Med."},{"key":"R85-20230911","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ."},{"key":"R86-20230911","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.cgh.2014.11.007","article-title":"Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants","volume":"13","author":"Lanas","year":"20152015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R87-20230911","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am Coll Cardiol."}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005344-201908000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T01:19:57Z","timestamp":1694395197000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005344-201908000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0000000000000697","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}